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ABSTRACT 
This article reviews the basic principles of immunization, iden- 
tifies the components of the practice of immuniz.ation, and 
points to some of the issues specific to that practice that will 
need to be taken into account as the vaccines of the future are 
coming close to availability. The purpose of immunization is to 
protect an individual from a specified infectious disease, from 
the earliest appropriate age, for as long as possible, using the 
fewest number of doses to achieve that immunity, and with 
the least possible risk from the procedure. For certain diseases, 
for example tetanus, the benefit of immunization is only to the 
vaccine recipient. In the case of vaccines such as polio vac- 
cine, there is a wider purpose. As well as protecting immu- 
nized individuals, there can be community benefit to individuals 
not immunized. When sufficiently high coverage is reached, 
transmission is interrupted and individuals not immunized are 
further protected. For routine immunization against any vac- 
cine-preventable disease, there needs to be the provision of 
routinely available processes that seek to promote the highest 
possible coverage in the target population; allow for the mea- 
surement of that achievement in an accurate and timely way; 
detect any possible adverse effects of the immunization; and 
sensitively and rapidly provide information on the target dis- 
eases. As the availability of existing resources for health pro- 
grams comes under increasing scrutiny, countries in all stages 
in development will need to consider the most co’st-effective 
use of resources, especially as countries are encouraged to 
become self-sufficient for financing their immunization pro- 
grams. Finding the necessary resources for presenlt vaccines, 
let alone the vaccines of the future, may be a considerable 
challenge. 
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It is clear that Jenner foresaw that smallpox vaccination 
could lead to the disappearance of smallpox from the 
world: “the annihilation of the Small Pox, the most dread- 
ful scourge of the human species, must be the fiial result 
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of this practice.“l Within his lifetime vaccination had 
spread to all continents, and hundreds of thousands of 
people had been vaccinated. It is difficult to identify any 
other process that so completely affects the human race, 
where the objective is to provide a product for every 
newborn child, and which comes close to that ambition. 
Immunization is one of the safest medical interventions 
and is probably the most cost effective of all health care 
initiatives.2 This article reviews the basic principles of 
immunization, identifies the components of the practice 
of immunization, and points to some of the issues spe- 
cific to that practice that will need to be taken into 
account as the vaccines of the future are coming close 
to availability. 
THEORY OF IMMUNIZATION 
The purpose of immunization is to protect an individual 
from a specified infectious disease, from the earliest 
appropriate age, for as long as possible, using the fewest 
number of doses to achieve that immunity, and with the 
least possible risk from the procedure. For many infec- 
tious diseases, immunity is passed from mother to baby, 
providing protection that may last a variable length of 
time. The duration of that protection may relate to the 
mother’s own exposure to the infectious agent: the 
infants of mothers who have had natural measles have 
higher antibodies at birth than infants born to mothers 
whose immunity is vaccine derived.’ Thereafter, the 
infant’s antibodies wane, and the child becomes suscep- 
tible to infection. Immunization offered at this time 
moves the recipient to the protected portion of the pop- 
ulation where, ideally, it remains for the rest of its life. In 
some cases, there may be waning immunity; in some 
cases there will be primary vaccine failure. This transition 
from one immunity status to another is used in the math- 
ematical modeling of immunization.4 
For certain diseases, for example tetanus, the bene- 
fit of immunization is only to the vaccine recipient. 
Because of the ubiquitous nature of tetanus spores, any 
individual not immunized remains at risk, and could con- 
tract tetanus on any occasion after being exposed appro- 
priately to that risk. Despite cases of tetanus falling 
progressively since the vaccine was introduced into the 
United Kingdom, a small number of cases still occur each 
year (Figure 1). It is notable that the disease affects mostly 
the elderly, and particularly women, as they were not 
subjected to immunization, being older than the targeted 
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Figure 1. Tetanus notifications for Office of National Statistics 
(England and Wales) 1969-1995. Inset: Number of cases of tetanus 
by age and sex, 1984-l 993. 
age when the program was introduced, nor were they 
immunized as part of military service. 
In the case of vaccines such as polio vaccine, there 
is a wider purpose. As well as protecting immunized indi- 
viduals, there can be community benefit to individuals 
not immunized. When sufficiently high coverage is 
reached, transmission is interrupted and individuals not 
immunized are further protected. This effect benefits 
those with valid contraindications who should not be 
immunized. Ultimately, when all countries interrupt trans 
mission of the causative agent, then global eradication 
can be contemplated. Figure 2 shows the impact of polio 
immunization in England and Wales. Although coverage 
for infants only rose above 90% in the 1980s the risk of 
wild virus polio had been eliminated considerably earlier. 
THE PRACTICE OF IMMUNIZATION Vaccine Supply and Vaccine Quality 
For routine immunization against any vaccine-preventable 
disease, there needs to be the provision of routinely avail- 
able processes that seek to promote the highest possible 
coverage in the target population, allow for the mea- 
surement of that achievement in an accurate and timely 
way, detect any possible adverse effects of the immu- 
nization, and sensitively and rapidly provide information 
on the target diseases. The latter may include estimations 
of the population’s protection against the diseases by 
age-specific seroepidemio1ogy.j 
Coverage and Resources 
The achievement of the desired levels of coverage can 
only be ensured if adequate resources are available for 
implementation of the program, adequate supplies of vac- 
cine are in place when needed, the program to deliver 
vaccine to the target population is operating efficiently, 
and the program is promoted effectively to health pro- 
fessionals and the public, creating demand. By 1990,80% 
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Figure 2. Notifications of paralytic poliomyelitis to Office of National 
Statistics, England and Wales 1940-1996. 
of the world’s children had received six essential vac- 
cines, diphtheria, tetanus, pertussis, polio, measles, and 
BCG, by their first birthday an outstanding achievement.’ 
However, in a number of countries, immunization cov- 
erage is falling. Examination of those countries report- 
ing the largest declines in coverage between 1993 and 
1994,’ shows that many have particular economic hard- 
ship, civil unrest, or both. Nevertheless, there are other 
countries where in spite of these factors, high levels of 
coverage are maintained. UNICEF data for 1993 reveal a 
number of countries where the annual gross national 
product (GNP) per capita is less than US $1000 and 
measles immunization coverage is over 90%; in contrast, 
three Western European countries with annual GNP per 
capita in excess of US $20,000, had measles immuniza- 
tion coverage from 50 to 70%.’ 
Industrialized countries are either self-sufficient for sup- 
plies of high quality vaccines, or are able to purchase 
them from multinational manufacturers. Vaccines are 
required to meet rigorous specifications for purity and 
potency, demonstrated by the manufacturer, and inde- 
pendently tested before use. Countries in development 
may import vaccines, requiring hard currency for their 
purchase, or may manufacture them locally. Where 
resources are severely restricted, some countries have 
depended until now on donated vaccines. It is now 
appreciated that countries should incorporate the pro- 
vision of vaccines into core national budgets, since the 
economic gains from the prevention of infectious disease 
far outweigh the costs.’ UNICEF and the World Health 
Organization (WHO) are promoting a vaccine indepen- 
dence initiative to help countries take on the resourcing 
of vaccines. Countries in the Region of the Americas 
share in a revolving fund arrangement that allows them 
to benefit from economies of scale in vaccine pricing, 
and reduces the need for hard currency As well as requir- 
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ing resources to purchase vaccines, countries need to be 
able to ensure that the vaccines used are of high quality. 
This may be difficult for some countries, especially those 
where there has been little investment in quality assur- 
ance and quality control. These issues will bec:ome even 
more significant as new vaccines become available. 
Although the greatest benefit may accrue to dleveloping 
countries, the ability to afford new vaccines is likely to 
be particularly challenging, if, as seems likely, new vac- 
cines cost more than existing products. The World Health 
Organization and UNICEF have developed a rnodel that 
groups countries according to their GNP per capita and 
population size. It is evident that for some countries, the 
relation between GNP and population indicates a con- 
tinuing need for direct financial support for vaccines, 
served by the international market, with UNICEF procur- 
ing on their behalf. For the most part, these are smaller 
countries that do not manufacture vaccines. With pro- 
gressive increases in GNP and population, there should 
be sustainable financing of vaccines, with the national 
governments meeting targeted self-financing levels.8 
Implementation of Immunization 
Services to implement immunization exist, in some form 
or another, in every country in the world. These services 
range from contractual financial arrangements between 
parents and health providers in private sector health care 
systems, to state-provided services, free to all, in public 
sector programs. In many countries, this latter situation 
has been formalized as the Expanded Program on Immu- 
nization (EPI), a WHO-initiated program that grew out of 
the smallpox eradication program in the early :198Os. The 
purpose of the EPI has been to guide countries to 
develop services to implement immunization, undertake 
surveillance, train immunization workers, and ensure that 
vaccines are provided in the best state possible. Ideally, 
EPI is integrated into primary health care and maternal 
child health services as a seamless web. Through its pro- 
vision of training materials and technical services, mobi- 
lization of international resources, and focus on particular 
objectives (such as polio eradication), EPI has become 
an institutionalized part of the health program of many 
countries. 
Building on an infrastructure of the immunization pro- 
gram, a number of strategies have been developed to 
implement immunization more effectively. The World 
Health Organization has identified the importance of 
missed opportunities and recommends a number of 
means of minimizing these.9 Some countries have relied 
on legal compulsion to achieve high coverage. However, 
examination of coverage by country reveals that excep- 
tionally high levels are also reached in some of those coun- 
tries where there is no legal compulsion. In the United 
States, all states have laws that require demonstration of 
immunization as a condition for school entry. Conse- 
quently, coverage at school entry is close to 100%. But 
such requirements can act against the epidemiologic best 
interests of disease prevention. For measles, the primary 
objective is to achieve the highest possible immunization 
coverage shortly after young children become suscepti- 
ble to measles. Despite the high coverage by school entry, 
coverage in 1992-1993 of 2-year-old American children 
was only 81%. lo In the measles resurgence between 
1989-1991, cases occurred predominantly in preschool 
children who had not been immunized.” 
In 1990, the United Kingdom adopted a novel strat- 
egy to promote the implementation of immunization 
through primary care. In place of the preexisting system 
of state payments per immunization, family doctors only 
receive payment for immunization when they attain quar- 
terly targets for cohorts of 2-year-old children for com- 
pletion of the primary immunizations, and a further target 
payment for the preschool boosters. If 70% coverage is 
reached, doctors receive payments that match the average 
income from immunization on the previous item of ser- 
vice basis. Three times the payment is awarded for the 
achievement of 90% coverage, or higher. No exclusions 
from the denominator population are allowed. This 
scheme has led to progressively higher proportions of 
family doctors reaching target payments, so that now, 
more than 90% of doctors are regularly exceeding their 
higher targets. l2 Figure 3 shows the progressive increase 
in the proportion of doctors reaching the 90% target pay- 
ment; fewer doctors reach only the 70% target, and 
accordingly, few fail to get any target payments. 
Promotion of Immunization 
In addition to providing services to deliver immunization, 
it is essential that there should be public acceptance or 
even demand for immunization. To undertake this effec- 
tively, a coordinated and appropriately resourced promo- 
tion program is required. In the United Kingdom, this 
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Figure 3. The proportion of general practitioners in the United King- 
dom reaching targets. Primary immunization series, April 1990 to April 
1994. 
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process starts with market research on parents and health 
professionals, to identify the key information needs for 
the target audience. This is followed by the development 
of a coordinated communication strategy that involves 
the provision of written materials for parents and health 
professionals, advertisements in appropriate newspapers 
and magazines, television and radio advertising, and the 
availability of materials appropriate for ethnic community 
groups. All materials developed in this process are mar- 
ket tested before publication or transmission. Through 
the use of media buying services, the highest possible 
exposure of the materials to the relevant target audience 
is ensured, giving the best return on investment. After 
each wave of immunization promotion, tracking studies 
are undertaken to identify the impact of the material. This 
information is fed back into the development process for 
the design of future campaigns. 
Surveillance of Target Diseases 
The measurement of immunization coverage provides an 
invaluable process indicator for the implementation of 
immunization programs. l3 However, it is the measure- 
ment of the outcome indicator that attests to the pro- 
gram’s achievements, or that identifies the program’s 
potential or real weaknesses. Susceptibility identifies its 
potential and preventable weakness, the occurrence of 
vaccine-preventable disease demonstrates real weakness. 
As immunization programs mature, the requirements for 
surveillance become more sophisticated. When disease 
is endemic, sentinel surveillance will suffice. As the objec- 
tives of an immunization program advance from control 
to elimination, or even eradication, surveillance must 
become sufficiently sensitive to be able to detect any 
cases, or even a potential for cases to occur. After many 
years of dependence on passive and often insensitive sur- 
veillance techniques, new surveillance initiatives are 
being developed. The foremost such development has 
been the application throughout Central and South Amer- 
ica and the Caribbean of acute flaccid paralysis (AFP) sur- 
veillance for the polio elimination initiative in the Region 
of the Americas. Based largely on the results of 3 years 
of AFP surveillance that demonstrated the ability to detect 
sensitively acute flaccid paralysis in children and show 
that none of them were caused by wild polio virus, the 
International Certification Commission of Poliomyelitis 
Eradication was able to conclude that wild virus 
poliomyelitis has been eliminated in the Americas.‘* As 
a result of the development of this surveillance system, 
other vaccine-preventable diseases, such as measles, are 
now under far better control. 
In the United Kingdom, surveillance of measles and 
rubella has been transformed from the reporting of sus- 
pected cases to the ability to confirm cases accurately 
and non-invasively through the nationwide availability of 
diagnosis through detection of salivary IgM on a single 
sample. l5 Less than 1% of tested cases are confirmed as 
measles; close to 60% of suspected cases are investigated 
with a saliva sample.16 
Surveillance of Adverse Events 
Just as surveillance systems become more sensitive with 
program maturity, surveillance of adverse events assumes 
progressively greater importance: as disease prevalence 
declines, parents are less concerned with the potential 
seriousness of the diseases and become more preoccu- 
pied with vaccine safety. l7 Since serious adverse reac- 
tions occur very rarely, surveillance needs to be sensitive; 
moreover, many of the events reported as vaccine 
adverse reactions occur independently of immunization. 
Thus, data are needed on events temporarily associated 
with immunization, and background rates of such events 
independent of immunization are also needed. Many 
countries have passive reporting systems for vaccine 
adverse events, but these are prone to considerable 
under-reporting and reporting bias and do not detect 
similar rare events occurring without a temporal asso- 
ciation with immunization. l8 An active reporting system 
has been developed in Canada, where there is surveil- 
lance in sentinel pediatric hospitals.19 Information is col- 
lected daily by dedicated nurses on all pediatric 
admissions with diagnoses that may have an association 
with immunization, and the immunization history is 
obtained. In the United Kingdom, sophisticated data 
linkage studies have been pioneered.20 Hospital discharge 
diagnosis codes on children in particular age groups are 
matched with community-held databases of immuniza- 
tion records, so that associations between hospital admis- 
sions and immunizations can be examined, comparing 
risk periods after immunizations with control periods 
outside of the risk periods. Such studies have demon- 
strated the risk of idiopathic thrombocytopenic purpura 
after measles-mumps-rubella (MMR) immunization 
(1:24,000 immunizations) and have shown that giving 
the third dose of diphtheria, tetanus toxoids, pertussis 
(DTP) vaccine before 6 months of age is associated with 
a fourfold lower frequency of postimmunization febrile 
seizures than if the third dose is given after 6 months of 
age. When DTP immunization is completed before 6 
months, there is no increased risk of febrile seizures fol- 
lowing immunization, compared with time periods out- 
side of the 72 hours after the procedure. 
IMMUNIZATION ISSUES FOR THE FUTURE 
Resources to Maintain Programs and Resources for 
Vaccines of the Future 
As the availability of existing resources for health pro- 
grams comes under increasing scrutiny, it is becoming 
routine to have to show cost-effectiveness predictions for 
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new health interventions. Such studies have hitherto 
been more often undertaken in industrialized countries, 
but it is probable that countries in all stages in devel- 
opment will need to consider the most cost-effective 
use of resources, especially as countries are en’couraged 
to become self-sufficient for financing their immunization 
programs. The World Development Report shows clearly 
that investing in vaccines is to be commended.2 How- 
ever, tension often exists in the resource justification in 
public sector health systems. Preventative programs are 
low-profile; they achieve undoubted long-term health 
gains and returns on investment, but the successes are 
often intangible, as absence of disease may not be eas- 
ily perceived. In contrast, curative services offer imme- 
diacy and high-profile public concern about the 
possibility of their lack of availability The results of cura- 
tive services are highly visible. Nevertheless, preventa- 
tive services, such as immunization, reach levels of 
cost-effectiveness that curative services cannot match. 
In public sector immunization programs, investment in 
vaccines requires the provision of “hard resources” from 
the budgets of Health Departments: vaccines must be 
purchased, there are real costs in the delivery of vac- 
cines to the recipient (payments to health providers, 
infrastructure costs, consumables), and there may be 
costs associated with adverse reactions. On the other 
hand, the gains are often “soft”: reductions in disease 
incidence, handicap, or death. Prevention of illness 
requiring hospital admission rarely leads to reductions in 
the facilities provided; rather they are used to treat other 
patients. The prevention of work days lost through ill- 
ness may contribute to overall economic success, but 
the gains do not accrue to the Health Departments that 
provided the initial resources for the prevention pro- 
gram. Thus, for the most part, in a cost-effectiveness 
model, program costs are real, and the effectiveness is 
mostly opportunity gain. 
Manufacturers of vaccines also have to demonstrate 
cost-effectiveness. Here the model is different and 
depends on the recycling of profit. Shareholders and 
investors expect a return on their investment. This comes 
from the manufacturers’ profits. But new initiatives must 
be resourced and the research and development costs 
are carried with the manufacturing cost and reflected in 
the vaccine price. This in turn produces profits. The 
whole of this process is dependent on time for return 
on investment, the effect of competition aIn market 
prices, and the risks of failed products in development. 
For the vaccine industry to remain healthy and compet- 
itive, and for national programs to continue to be able to 
provide high-quality and up-to-date products, there will 
have to be mutual understanding of the needs of each 
party to fulfill its obligations for its relevant cost-effec- 
tiveness requirements. The present differenti.al pricing 
of vaccines for industrialized and developing countries 
will probably continue as the only way for new vaccines 
to be available to developing countries. Where a new 
vaccine is used in both circumstances, the industrialized 
countries may be carrying the development costs, 
whereas the developing countries pay just the manufac- 
turing cost. The situation becomes much less clear if 
there is little application for the product in industrialized 
countries. 
New Surveillance Techniques 
Non-invasive confirmation of measles, mumps, and 
rubella using a single saliva sample is already routinely 
available in the United Kingdom. But the laboratory tech- 
nique (antibody capture enzyme-linked immunosorbent 
assay [ELISA]) requires sophisticated services, and the 
result is not immediately available as would be ideal for 
outbreak control purposes. Rapid diagnostic tests for field 
use will contribute significantly to elimination or eradi- 
cation programs; identification of viral antigens would 
allow action before chains of transmission were set up, 
as distinct from the time lag for tests that depend on 
detection of antibodies. Molecular genealogy is already 
allowing polio viruses to be linked to their probable 
places of origin; similar techniques are being applied to 
measles viruses to identify imported strains, and mumps 
vaccine viruses can be distinguished from wild strains. 
These techniques are likely to revolutionize the surveil- 
lance initiatives of the future. With better surveillance, 
mathematical models will be used increasingly to predict 
the impact of immunization programs, so that different 
strategies can be tested and the most effective selected 
for implementation. In all immunization programs, it is 
likely that there will be continuing demands for demon- 
stration of vaccine safety. These demands will not be sat- 
isfied with the presently available adverse event 
surveillance systems, along with the lack of diagnostic 
tests that distinguish temporal events from reactions that 
are causal. Because of the rarity of serious adverse reac- 
tions, it will be difficult to be confident before vaccines 
are introduced that rare reactions will not occur. Post- 
marketing surveillance may offer some comfort, until 
problems are identified, when the cpnsequences of such 
detection can jeopardize the public’s confidence in the 
whole immunization program. 
CONCLUSION 
Two hundred years after Jenner’s discovery, immuniza- 
tion programs exist in every country in the world and 
immunization is acknowledged as the most cost-effective 
medical intervention. Smallpox has been eradicated, polio 
eradication is on course, and measles could follow. But 
there is still room for considerable improvement in the 
delivery of vaccines and in surveillance of their effects, 
both on disease and on the vaccine recipient. The appli- 
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cation of presently available scientific advances will trans- 
form the vaccines of the future, but finding the necessary 
resources may be a considerable challenge. The vaccines 
of the future need to be safe, effective, affordable, and 
available. National authorities will need to ensure that 
they are provided for all who will benefit. 
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